Champions Oncology, Inc. (CSBR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 32 | 41 | 49 | 54 | 50 | 57 | 59 | 61 |
| Operating profit | $m | -1 | -1 | ||||||
| Net profit | $m | -2 | 0 | 1 | -5 | -7 | 5 | -1 | -1 |
| EPS reported | $ | -0.08 | -0.08 | ||||||
| Operating cashflow per share | $ | -0.32 | -0.32 | ||||||
| Capex per share | $ | 0.04 | 0.04 | ||||||
| FCF per share | $ | -0.36 | -0.36 | ||||||
| Free cash flow | $m | -5 | -6 | ||||||
| Net debt | $m | -5 | -3 | ||||||
| Book value equity | $m | 4 | 4 | ||||||
| Book value per share | $ | 0.28 | 0.28 | ||||||
| Number of shares | m | 13.83 | 13.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 49.00 | - | ||||||
| P/B LTM | x | 20.93 | 25.09 | ||||||
| P/S LTM | x | 1.04 | 1.61 | ||||||
| P/FCF LTM | x | -16.37 | -15.91 | ||||||
| EV/EBITDA LTM | x | 25.61 | 210.26 | ||||||
| EV/Sales LTM | x | 1.26 | 1.22 | ||||||
| Earnings Yield LTM | % | +2.13% | -1.63% | ||||||
| FCF Yield | % | -6.11% | -6.28% | ||||||
| Quality | |||||||||
| ROE | % | -29.83% | -29.56% | ||||||
| ROIC | % | -13.28% | -13.15% | ||||||
| Operating margin | % | -1.92% | -1.92% | ||||||
| Gross margin | % | +48.00% | +48.00% | ||||||
| FCF/Sales | % | -8.47% | -8.47% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +4.36% | +20.95% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.12 | -0.56 | ||||||
| Net Debt/EBITDA | x | -0.80 | -0.61 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +2.20% | ||||||
| Net debt/Equity | x | -1.24 | -0.84 | ||||||
| Gross debt/equity | x | 1.15 | 2.82 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free